ANIK Q3 2018 Earnings — Anika Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ANIKAnika Therapeutics, Inc.

$208M

Q3 2018 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$27M-1.5% YoY

Gross Profit

$19M69.1% margin

Operating Income

$9M32.0% margin

Net Income

$8M28.4% margin

EPS (Diluted)

$0.53

QoQ Revenue Growth

-12.3%

Cash Flow

Operating Cash Flow

$11M

Free Cash Flow

$10M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$269M

Total Liabilities

$14M

Stockholders' Equity

$255M

Cash & Equivalents

$82M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$27M	-1.5%
Gross Profit	$19M	$21M	-11.6%
Operating Income	$9M	$10M	-16.5%
Net Income	$8M	$7M	+10.3%

Revenue Segments

Product

$27M50%

Orthobiologics

$24M45%

Manufactured Product, Other

$1M3%

Surgical

$1M2%

Dermal

$80,0000%

Geographic Segments

UNITED STATES

$22M87%

Europe

$3M13%